Compare 3M Company (MMM) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
3M Company vs Neurocrine Biosciences Inc — how do they compare? 3M Company trades at $164.86 (market cap $86.39B), while Neurocrine Biosciences Inc trades at $155 (market cap $15.77B). The key difference: 3M Company is far larger — about 5.5× Neurocrine Biosciences Inc's market cap, and 3M Company pays a 1.86% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MMM | NBIX | |
|---|---|---|
Market Cap | $86.39B | $15.77B |
Sector | Industrials | Health |
52-Week High | $183.79 | $185.50 |
52-Week Low | $141.10 | $123.10 |
Enterprise Value | $95.61B | $15.78B |
Dividend Yield | 1.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
3M (MMM) trades at $167.52, down 0.62% on the day, with a bearish technical signal but strong recent earnings beats. The company shows solid profitability with an 11.9% net income margin and 82.77% ROE, though revenue has declined from 2022 peaks. Positive news highlights strength in transportation, electronics, and safety segments, while consumer demand remains soft.
The stock offers a balanced outlook: analyst consensus is a Buy with a $173 price target, but high debt and cost pressures pose risks. Earnings momentum from industrial growth supports upside, yet valuation multiples like a 29.75 P/E suggest limited margin for error. Investors should weigh robust fundamentals against macroeconomic and segment-specific headwinds.
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
